… in patients with primary progressive multiple sclerosis … multiple sclerosis: a geographical
based study. 5. The clinical features and natural history of primary progressive multiple sclerosis…

… disease activity in relapsing-remitting multiple sclerosis (MS). We evaluated rituximab in
adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks. …

… detection of MRI-enhancing lesions in patients with primary progressive multiple sclerosis. …
movements with clinical correlations in patients with primary progressive multiple sclerosis. …

… Patients with primary progressive (PP) multiple sclerosis represent a subgroup with clinical
… (RR) multiple sclerosis or secondary progressive (SP) multiple sclerosis (Thompson et al., …

Emerging evidence underlines the importance of micro(mi)RNAs in the pathogenesis of
multiple sclerosis (MS). Free-circulating miRNAs were investigated in serum from MS patients …

… major event in the pathogenesis of multiple sclerosis, which is an … multiple sclerosis with
relapses and the primary progressive … are involved in primary progressive multiple sclerosis, we …

… Objective To determine the effect of rituximab on cerebrospinal fluid B cells in patients
with multiple sclerosis. Design Four patients with primary progressive multiple sclerosis were …

… B) from healthy control subjects, patients with primary progressive multiple sclerosis (PPMS),
and patients with secondary progressive multiple sclerosis (SPMS). Compared with healthy …

… in patients with primary progressive multiple sclerosis. … in early primary progressive multiple
sclerosis. By combining these … 21 patients with primary progressive multiple sclerosis within …

… on patients with primary progressive MS. A healthy … patients with primary progressive MS
(PPMS). In addition to being less prevalent than relapsing–remitting and secondary progressive …